TenNor Therapeutics was established in 2013 with operations in the historic city of Suzhou, China. The company specializes in research and development of new drugs for the treatment of digestive diseases caused by pathogens, including those resistant to available antibiotics.
Protected by 11 patent families, the company possesses a strong drug development portfolio created through the acquisition of assets from Cumbre and patents from the TB Alliance. The most advanced drug candidate, TNP-2092, is a dual-action molecule. It is active against Helicobacter pylori (H. pylori), Clostridium difficile (C. difficile) and several other important gastrointestinal pathogens responsible for some of the most common and serious digestive diseases. TNP-2092 is active against clinical isolates that are resistant to available antibiotics and has a low propensity for resistance development. Cumbre has completed Phase I single and multiple ascending dose clinical trials for TNP-2092 via intravenous administration that have demonstrated excellent safety and tolerability. TenNor is developing TNP-2092 as an oral, locally active drug for the treatment of digestive diseases caused by H. pylori infection to address the major unmet medical needs associated with the standard triple and bismuth-containing quadruple therapies. TenNor plans to further expand its product portfolio into other digestive disease areas including C. difficile infection and Crohn’s disease.
TenNor is currently focusing on new drug development in China and plans to seek partnerships for global development at an appropriate stage.